Sponsor content
63 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryOrserdu is approved for the treatment of advanced breast cancer in postmenopausal women, and men. Orserdu contains the active ingredient elacestrant.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ORSERDU elacestrant (as dihydrochloride) 345 mg film coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ORSERDU elacestrant (as dihydrochloride) 86 mg film coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Seremind Lavender Oil.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALLERTINE MELTLETS bilastine 20 mg orally disintegrating tablet blister pack.
-
Prescription medicine registrationActive ingredients: elacestrant dihydrochloride.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALLERTINE bilastine 20 mg tablet blister pack.
-
Cancellation by sponsorRequested by A Menarini Australia Pty Ltd
-
Cancellation by sponsorRequested by A Menarini Australia Pty Ltd
-
Cancellation by sponsorRequested by A Menarini Australia Pty Ltd